primary disease | sex | age at HCC | duration to carcinogenesis (year) | HCC stage | initial treatment | initial treatment effect | molecular-targeted drugs |
---|---|---|---|---|---|---|---|
AIH | male | 73 | 10 | 3 | TACE | CR | intolerance |
AIH-PBC | male | 77 | 0 | 3 | TACE | SD | - |
AIH | male | 71 | 14 | 2 | TACE | CR | PR |
AIH | female | 79 | 20 | 1 | thermal ablation | PD | - |
AIH | female | 76 | 0 | 3 | surgery | PD | intolerance |
AIH-PBC | female | 71 | 8 | 1 | thermal ablation | CR | - |
AIH | female | 54 | 14 | 2 | thermal ablation | CR | - |
AIH | male | 70 | 1 | 1 | TACE | PD | - |
AIH | female | 79 | 5 | 2 | thermal ablation | CR | - |
AIH | female | 73 | 0 | 3 | TACE | - | - |
AIH | female | 71 | 0 | 2 | surgery | CR | - |
AIH | female | 80 | 9 | 2 | thermal ablation | CR | - |